Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2326 to 2340 of 7711 results

  1. Seladelpar for previously treated primary biliary cholangitis ID6429

    In development [GID-TA11540] Expected publication date: 10 September 2025

    Technology appraisal guidance
    In development

  2. Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]

    In development [GID-TA11498] Expected publication date: 10 September 2025

    Technology appraisal guidance
    In development

  3. Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]

    In development [GID-HST10062] Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  4. Dupilumab for treating severe chronic rhinosinusitis with nasal polyposis (Review of TA648) [ID6480]

    In development [GID-TA11630] Expected publication date: 11 September 2025

    Technology appraisal guidance
    In development

  5. Artificial intelligence technologies to aid the opportunistic detection of vertebral fragility fractures on radiographic images

    In development [GID-HTE10059] Expected publication date: 20 August 2025

    Health technology evaluations
    In development

  6. Pneumonia QS update

    In development [GID-QS10190] Expected publication date: 14 August 2025

    Quality standard
    In development

  7. Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]

    In development [GID-TA10165] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating primary advanced or recurrent endometrial cancer ID6381

    In development [GID-TA11461] Expected publication date: 16 April 2025

    Technology appraisal guidance
    In development

  9. Human normal immunoglobulin for preventing infection in chronic lymphocytic leukaemia TSID 12043

      Status ...

    Technology appraisal guidance
    Topic selection

  10. Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]

    In development [GID-TA11277] Expected publication date: 13 August 2025

    Technology appraisal guidance
    In development

  11. Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]

    In development [GID-TA11554] Expected publication date: 12 November 2025

    Technology appraisal guidance
    In development

  12. Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235

    In development [GID-TA11246] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301]

    Awaiting development [GID-TA11338] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312

    Awaiting development [GID-TA11329] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]

    In development [GID-TA10948] Expected publication date: TBC

    Technology appraisal guidance
    In development